Wall Street analyst estimates for Curis, Inc. (CRIS): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 16 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 18 |
| Avg rating (1-5) | 0.89 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-2.29 | ||
| 2026-08-14 | $-4.02 | $-6.95 | +42.2% |
| 2026-05-12 | $-25.00 | $-5.80 | -331.0% |
| 2026-03-19 | $24.60 | $-8.72 | +382.1% |
| 2025-11-06 | $-9.80 | $-12.40 | +21.0% |
| 2025-08-05 | $-13.60 | $-39.80 | +65.8% |
| 2025-05-06 | $-25.00 | $-22.80 | -9.6% |
| 2025-03-31 | $-25.00 | $-27.20 | +8.1% |
Valuation Ratios
| Price / Book | 0.48 |
| EV / EBITDA | 0.09 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.5M | $9.9M | $10.4M | $10.0M | $10.8M | $10.6M | $10.2M | $10.0M | $10.9M | $9.4M |
| Cost of Revenue | $399000 | $496000 | $563000 | $503000 | $534000 | $533000 | $257000 | $212000 | $98000 | $45000 |
| Gross Profit | $7.1M | $9.4M | $9.9M | $9.5M | $10.3M | $10.1M | $9.9M | $9.8M | $10.8M | $9.4M |
| Research & Development | $31.6M | $33.3M | $24.4M | $22.3M | $23.1M | $34.9M | $43.3M | $39.5M | $38.6M | $28.3M |
| Selling, General & Admin | $15.6M | $25.8M | $14.8M | $11.6M | $12.1M | $17.3M | $19.6M | $18.6M | $16.8M | $14.0M |
| Operating Expenses | $47.2M | $59.2M | $39.2M | $33.9M | $35.2M | $52.2M | $62.9M | $58.1M | $55.4M | $42.3M |
| Operating Income | -$58.0M | -$49.8M | -$29.3M | -$24.4M | -$24.9M | -$42.1M | -$53.0M | -$48.3M | -$44.5M | -$32.9M |
| EBITDA | -$57.4M | -$49.1M | -$28.5M | -$27.2M | -$24.7M | -$40.8M | -$51.7M | -$45.1M | -$42.6M | -$5.2M |
| Interest Expense | $2.8M | $4.0M | $3.9M | $4.8M | $5.1M | $4.5M | $4.8M | $2.0M | $615000 | $2.2M |
| Pre-tax Income | -$60.4M | -$53.3M | -$32.6M | -$32.1M | -$29.9M | -$45.4M | -$56.7M | -$47.4M | -$43.4M | -$7.6M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$60.4M | -$53.3M | -$32.6M | -$32.1M | -$29.9M | -$45.4M | -$56.7M | -$47.4M | -$43.4M | -$7.6M |
| EPS | $-900.00 | $-3575.20 | $-393.40 | $-387.40 | $-245.80 | $-198.40 | $-242.80 | $-179.20 | $-137.60 | $-11.60 |
| EPS (Diluted) | $-900.00 | $-3575.20 | $-393.40 | $-387.40 | $-245.80 | $-198.40 | $-242.80 | $-179.20 | $-137.60 | $-11.60 |
| Shares Outstanding (Diluted) | $66392 | $14913 | $82795 | $82951 | $121675 | $228922 | $233481 | $264664 | $315314 | $658201 |
Price
| Price | $1.12 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ASBP · ATHA · BCTX · CTXR · ENTO · HOTH · ICU
Explore sector: Healthcare · Biotechnology
More sections of CRIS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks